- Home
- OFS vs IMA Comparison
OFS vs IMA Comparison
Compare OFS & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFS | IMA |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.1M | 65.4M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | OFS | IMA |
|---|---|---|
| Price | $4.33 | $7.07 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 75.1K | 34.8K |
| Earning Date | 03-02-2026 | 03-18-2026 |
| Dividend Yield | ★ 15.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $42,970,000.00 | $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.28 | $5.70 |
| 52 Week High | $9.80 | $18.00 |
Technical Indicators
Market Signals| Indicator | OFS | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 35.95 | 50.67 |
| Support Level | $4.91 | $6.92 |
| Resistance Level | $5.01 | $7.60 |
| Average True Range (ATR) | 0.25 | 0.45 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 11.31 | 62.26 |
Price Performance
Historical ComparisonAbout OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.